CMV reactivation/disease in 33 patients who did not receive CMV-specific T-cell therapy
Patient no. . | pp65 antigenemia* . | CMV disease (onset after transplantation, wk) . | Outcome (time after diagnosis, wk) . |
|---|---|---|---|
| 1 | 29 ± 22 | — | — |
| 2 | 20/5 | — | — |
| 3 | 33 | — | — |
| 4 | 8 ± 3 | — | — |
| 5 | 12 ± 10 | — | — |
| 6 | 2/10 | — | — |
| 7 | 20 | — | — |
| 8 | 13 | — | — |
| 9 | 5 ± 2 | Hepatitis + enteritis (7) | Resolution (2) |
| 10 | 7 ± 4 | IP (12) | Death (2) |
| 11 | 15 ± 14 | — | — |
| 12 | 2/2 | — | — |
| 13 | 14 ± 8 | — | — |
| 14 | 23 ± 20 | — | — |
| 15 | 43 ± 35 | IP (11) | Death (3) |
| 16 | 109 ± 53 | IP + CNS (15) | Death (2) |
| 17 | 22 ± 16 | — | — |
| 18 | 95 | — | — |
| 19 | 7 ± 6 | — | — |
| 20 | 128 ± 70 | Hepatitis (13) | Death (2) |
| 21 | 21 ± 16 | — | — |
| 22 | 39 ± 20 | IP (10) | Death (4) |
| 23 | 8 ± 2 | — | — |
| 24 | 6 ± 4 | IP + CNS (12) | Death (4) |
| 25 | 38 ± 27 | IP (14) | Death (4) |
| 26 | 77 ± 52 | IP (15) | Death (4) |
| 27 | 19 ± 16 | — | — |
| 28 | 34 | Cystitis (8) | Resolution (6) |
| 29 | 10 ± 3 | — | — |
| 30 | 13 ± 4 | — | — |
| 31 | 21 ± 11 | IP (11) | Resolution (5) |
| 32 | — | — | — |
| 33 | 9 ± 4 | IP (12) | Death (4) |
Patient no. . | pp65 antigenemia* . | CMV disease (onset after transplantation, wk) . | Outcome (time after diagnosis, wk) . |
|---|---|---|---|
| 1 | 29 ± 22 | — | — |
| 2 | 20/5 | — | — |
| 3 | 33 | — | — |
| 4 | 8 ± 3 | — | — |
| 5 | 12 ± 10 | — | — |
| 6 | 2/10 | — | — |
| 7 | 20 | — | — |
| 8 | 13 | — | — |
| 9 | 5 ± 2 | Hepatitis + enteritis (7) | Resolution (2) |
| 10 | 7 ± 4 | IP (12) | Death (2) |
| 11 | 15 ± 14 | — | — |
| 12 | 2/2 | — | — |
| 13 | 14 ± 8 | — | — |
| 14 | 23 ± 20 | — | — |
| 15 | 43 ± 35 | IP (11) | Death (3) |
| 16 | 109 ± 53 | IP + CNS (15) | Death (2) |
| 17 | 22 ± 16 | — | — |
| 18 | 95 | — | — |
| 19 | 7 ± 6 | — | — |
| 20 | 128 ± 70 | Hepatitis (13) | Death (2) |
| 21 | 21 ± 16 | — | — |
| 22 | 39 ± 20 | IP (10) | Death (4) |
| 23 | 8 ± 2 | — | — |
| 24 | 6 ± 4 | IP + CNS (12) | Death (4) |
| 25 | 38 ± 27 | IP (14) | Death (4) |
| 26 | 77 ± 52 | IP (15) | Death (4) |
| 27 | 19 ± 16 | — | — |
| 28 | 34 | Cystitis (8) | Resolution (6) |
| 29 | 10 ± 3 | — | — |
| 30 | 13 ± 4 | — | — |
| 31 | 21 ± 11 | IP (11) | Resolution (5) |
| 32 | — | — | — |
| 33 | 9 ± 4 | IP (12) | Death (4) |
— indicates no manifestations of CMV disease and negative antigenemia; IP, interstitial pneumonia; CNS, central nervous system involvement.
Positive antigenemias (no. of positive cells/200 000 cells) detected weekly for up to 12 weeks after withdrawing antiviral foscarnet prophylaxis, at 20 days after transplantation. Single number indicates one episode of reactivation. Two numbers indicate 2 episodes of reactivation. Mean ± SD indicates 3 or more episodes of reactivation